CordenPharma Colorado Increases US Peptide Manufacturing Capacity

SourceContract Pharma
Date Published11/25/2020
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name CordenPharma Colorado
Parent companyInternational Chemical Investors Group
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2020
Domestically, the work will be done:In-house
Country(ies) from which reshored:Germany
City reshored to:Boulder
State(s) reshored to:CO
If relevant, work nearshored to:-
Product(s) reshoredlow to mid-kg scale range peptides, peptide APIs
What domestic positive factors made reshoring more attractive?Higher productivity, Lead time/Time to market, Lean/other business process improvement techniques, Skilled workforce availability/training, Under-utilized capacity, Other, Covid-19
Find Reshoring Articles